UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 113

Sortiert nach

Most random gene expression signatures are significantly associated with breast cancer outcome

PLoS computational biology, 2011-10, Vol.7 (10), p.e1002240-e1002240

2011

Volltextzugriff (PDF)

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach

JNCI : Journal of the National Cancer Institute, 2020-07, Vol.112 (7), p.708-719

2020

Volltextzugriff (PDF)

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

Clinical cancer research, 2019-06, Vol.25 (12), p.3581-3588

2019

Volltextzugriff (PDF)

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer

Cancer discovery, 2022-04, Vol.12 (4), p.1022-1045

2022

Volltextzugriff (PDF)

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer

Breast cancer research : BCR, 2019-02, Vol.21 (1), p.25-25, Article 25

2019

Volltextzugriff (PDF)

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Clinical cancer research, 2017-08, Vol.23 (15), p.4323-4334

2017

Volltextzugriff (PDF)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Nature communications, 2023-11, Vol.14 (1), p.7053-7053, Article 7053

2023

Volltextzugriff (PDF)

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Nature communications, 2023-11, Vol.14 (1), p.7018-7018, Article 7018

2023

Volltextzugriff (PDF)

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Nature communications, 2023-12, Vol.14 (1), p.8223-8223, Article 8223

2023

Volltextzugriff (PDF)

A measure of the signal-to-noise ratio of microarray samples and studies using gene correlations

PloS one, 2012-12, Vol.7 (12), p.e51013-e51013

2012

Volltextzugriff (PDF)

Data-driven risk identification in phase III clinical trials using central statistical monitoring

International journal of clinical oncology, 2016-02, Vol.21 (1), p.38-45

2016

Volltextzugriff (PDF)

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges

Journal of clinical medicine, 2023-01, Vol.12 (3), p.953

2023

Volltextzugriff (PDF)

A statistical approach to central monitoring of data quality in clinical trials

Clinical trials (London, England), 2012-12, Vol.9 (6), p.705-713

2012

Volltextzugriff (PDF)

Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome

EBioMedicine, 2020-06, Vol.56, p.102793-102793, Article 102793

2020

Volltextzugriff (PDF)

Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016-01, Vol.19 (1), p.24-30

2016

Volltextzugriff (PDF)

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis

NPJ breast cancer, 2022-07, Vol.8 (1), p.79-79, Article 79

2022

Volltextzugriff (PDF)

Timing evolution of lobular breast cancer through phylogenetic analysis

EBioMedicine, 2022-08, Vol.82, p.104169-104169, Article 104169

2022

Volltextzugriff (PDF)

Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring

Clinical trials (London, England), 2019-10, Vol.16 (5), p.512-522

2019

Volltextzugriff (PDF)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

NPJ breast cancer, 2021-09, Vol.7 (1), p.125-125, Article 125

2021

Volltextzugriff (PDF)

Use of the Beta-Binomial Model for Central Statistical Monitoring of Multicenter Clinical Trials

Statistics in biopharmaceutical research, 2017-01, Vol.9 (1), p.1-11

2017

Volltextzugriff (PDF)

Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex

Journal for immunotherapy of cancer, 2022-06, Vol.10 (6), p.e004820

2022

Volltextzugriff (PDF)

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

NPJ breast cancer, 2022-03, Vol.8 (1), p.38-1, Article 38

2022

Volltextzugriff (PDF)

Gene Expression in Human Thyrocytes and Autonomous Adenomas Reveals Suppression of Negative Feedbacks in Tumorigenesis

Proceedings of the National Academy of Sciences - PNAS, 2006-01, Vol.103 (2), p.413-418

2006

Volltextzugriff (PDF)

InSilico DB genomic datasets hub: an efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor

Genome biology, 2012-11, Vol.13 (11), p.R104-R104

2012

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(106)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(62)
Life Sciences & Biomedicine
(50)
Humans
(43)
Female
(26)
Breast Cancer
(19)
Oncology
(19)
Gene Expression
(15)
Life Sciences
(14)
Middle Aged
(13)
Adult
(12)
Male
(11)
Tumors
(11)
Animals
(10)
Breast Neoplasms - Genetics
(10)
Immunology
(10)
Science & Technology - Other Topics
(10)
Aged
(9)
Biological And Medical Sciences
(9)
Breast Neoplasms - Drug Therapy
(9)
General & Internal Medicine
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Most random gene expression signatures are significantly associated with breast cancer outcome

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

A measure of the signal-to-noise ratio of microarray samples and studies using gene correlations

Data-driven risk identification in phase III clinical trials using central statistical monitoring

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges

A statistical approach to central monitoring of data quality in clinical trials

Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome

Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis

Timing evolution of lobular breast cancer through phylogenetic analysis

Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Use of the Beta-Binomial Model for Central Statistical Monitoring of Multicenter Clinical Trials

Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Gene Expression in Human Thyrocytes and Autonomous Adenomas Reveals Suppression of Negative Feedbacks in Tumorigenesis

InSilico DB genomic datasets hub: an efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor

Suchergebnisse filtern